Founder / Editor-in-Chief
Dr. Jo-Fan Pan
PhD, University of Manchester; BSN, National Taiwan University. Leads Drugnews topic selection, business-analysis frameworks, long-form structure, and reader communication.
Official Site
Drugnews｜Biotech Business Analysis
Drugnews turns clinical data, company strategy, licensing activity, and capital-market signals into clear business judgment for biotech and pharmaceutical readers.
Taiwan-based biotech and pharmaceutical business intelligence for global readers.
T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability
PD-1 blockade, CAR-T and T-cell engagers ultimately depend on T cells that can expand, renew and persist. This analysis connects exhaustion biology, product engineering and clinical evidence to the next competitive threshold in immunotherapy.
Clinical data
Company strategy
Capital-market judgment
Read full analysis
Editorial Standard
From science to market judgment.
We cover company research, clinical and CMC risks, licensing and BD, valuation, and capital-market signals. The goal is not to summarize news, but to explain which evidence can change business value.
Reading Paths
Follow Drugnews by research need
Start from timely English analysis, then move into research frameworks, paid deeper work, or company-service collaborations when needed.
01
02
03
04
Latest English Articles
Reader-first biotech and pharmaceutical business analysis translated and edited for professional English readers.
Research Guides
Evidence-first frameworks for clinical endpoints, regulatory milestones, and licensing economics.
In-depth Research
Deeper company tracking and industry context for readers who need repeatable biotech business judgment.
Company Services
Investor-facing biotech content, market storytelling, and English communication support for company teams.
Team
Two biomedical PhDs translating science into business judgment.
Drugnews is built by Dr. Jo-Fan Pan and Dr. Chuan-Sheng Lin, combining clinical medicine, biotech R&D, business development, and capital-market perspectives. The editorial goal is to turn biotech information into research material readers can inspect, compare, and track.
Partner / Scientific Strategy
Dr. Chuan-Sheng Lin
Biomedical dual-PhD background with more than 15 years across the biotech and pharmaceutical R&D value chain, helping review scientific evidence, technical barriers, and development risk.